Oncodesign Precision Medicine S.A Logo

Oncodesign Precision Medicine S.A

Develops precision therapies & diagnostics for resistant and metastatic cancers.

ALOPM | Euronext Access Plus

Overview

Corporate Details

ISIN(s):
FR001400CM63
LEI:
969500ZDX1IY47LDL876
Country:
France
Address:
18 RUE JEAN MAZEN, 21000 DIJON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company established in 2022, specializing in precision medicine. The company's mission is to discover and develop innovative therapeutic and diagnostic solutions to combat therapeutic resistance and metastasis in cancer. OPM's patient-centric approach leverages innovative technologies, including artificial intelligence, to identify novel therapeutic targets and advance a pipeline of preclinical candidates. The core focus is on providing effective treatments for patients with resistant and metastatic cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-11 18:00
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 466.5 KB
2025-05-06 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 216.8 KB
2025-04-17 18:00
Capital/Financing Update
Inside Information / Other news releases
English 341.8 KB
2025-04-17 18:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 331.1 KB
2025-04-03 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 364.7 KB
2025-04-03 18:00
Earnings Release
Inside Information / News release on accounts, results
English 379.5 KB
2025-03-24 18:11
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 540.6 KB
2025-03-24 18:11
Legal Proceedings Report
Inside Information / Other news releases
English 629.3 KB
2025-03-04 17:45
Board/Management Information
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
French 293.7 KB
2025-03-04 17:45
Board/Management Information
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
English 287.9 KB
2025-01-08 18:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 604.4 KB
2024-12-20 08:00
Regulatory News Service
Inside Information / Other news releases
English 296.9 KB
2024-12-20 08:00
M&A Activity
Informations privilégiées / Autres communiqués
French 284.3 KB
2024-10-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 310.0 KB
2024-10-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 312.5 KB

Automate Your Workflow. Get a real-time feed of all Oncodesign Precision Medicine S.A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncodesign Precision Medicine S.A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncodesign Precision Medicine S.A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400

Talk to a Data Expert

Have a question? We'll get back to you promptly.